Evidence map›Paper›PMID 41416809›Full record

ArticleAntimicrobial agents and chemotherapy2026

Monthly dalbavancin dosing for suppressive therapy: a pharmacokinetic estimation analysis and case series.

Wesley D Kufel, Kristen Tudahl, Paul Hutson, Rahul Mahapatra, Warren Rose, Cecilia Volk

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Wesley D KufelState University of New York Binghamton School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA.ORCID 0000-0001-7703-096X
Kristen TudahlSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Paul HutsonSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Rahul MahapatraState University of New York Upstate Medical University, Syracuse, New York, USA.
Warren RoseSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-5012-5993
Cecilia VolkSchool of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.ORCID 0000-0001-6749-4170

Funding

University of Wisconsin Institute for Clinical and Translational ResearchUL1TR002373 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI ELIZABETH S BURNSIDE, Allan R. Brasier · 2017 to 2026
$75.9M
Institutional Career Development CoreKL2TR002374 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI Bo Liu, Marin Leigh Schweizer · 2017 to 2026
$9.7M
NCATS NIH HHS KL2 TR002374NCATS NIH HHS UL1 TR002373
6 · The paper itself

Abstract

Retained hardware/prosthetic infections frequently require antimicrobial suppression therapy. Treatment options are often limited by resistance, allergies, and dosing frequencies. Dalbavancin (DAL) is a potentially attractive option for suppression of gram-positive infections given its potential for infrequent dosing. However, optimal DAL suppression dosing is unknown. An

Indexed as

Anti-Bacterial AgentsTeicoplaninAdultAgedComputer SimulationFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedAnti-Bacterial AgentsdalbavancinTeicoplanindalbavancinpharmacokineticsuppression

Identifiers

PMID41416809
PMCPMC12888850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.